• Adverse Events Related to Excimer Laser Coronary Atherectomy: Analysis of the FDA MAUDE Database

    Excimer laser coronary atherectomy (ELCA) is utilized as adjunctive therapy in percutaneous coronary intervention (PCI) for moderately calcified lesions, chronic total occlusions, in-stent restenosis, under-expanded stents, and balloon-uncrossable lesions. We interrogated the post-marketing surveillance data from the U.S. Food and Drug Administration (FDA) Manufacturer and User Facility Device Experience (MAUDE) database to evaluate the complications associated with ELCA use [1].

    Author bio

    Cardiovascular Revascularization Medicine Volume 27, June 2021, Pages 88-89

    Source:

    Read the full article on Science Direct: Adverse Events Related to Excimer Laser Coronary Atherectomy: Analysis of the FDA MAUDE Database

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Review our Privacy Policy for more details